NCT06642506View on ClinicalTrials.gov

Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma

Active, not recruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 6, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2025

Conditions
Esophagus AdenocarcinomaEsophagus CancerMetabolomeMass SpectrometryPrecision MedicineOncology Patients Receiving ChemotherapyMetabolomicsChemoresistance
Trial Locations (1)

81377

Department of General, Visceral and Transplantation Surgery, LMU University Hospital, Munich

All Listed Sponsors
collaborator

Max Planck Institute of Biochemistry, Department of Proteomics and Signal Transduction, München, Germany

UNKNOWN

collaborator

Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany

OTHER

lead

Ludwig-Maximilians - University of Munich

OTHER

NCT06642506 - Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma | Biotech Hunter | Biotech Hunter